Portola Pharmaceuticals Appoints Dr. David C. Stump to Board of Directors
24 Septembre 2015 - 11:31PM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced the
appointment of David C. Stump, M.D., to its board of directors. Dr.
Stump most recently served as executive vice president, research
and development, at Human Genome Sciences, Inc.
"Dr. Stump has over 25 years of experience, most notably at
Genentech and Human Genome Sciences, bringing some of the most
successful drugs for heart disease, stroke, B-cell lymphoma and
other cancers through the clinic and regulatory process to the
market," said Bill Lis, chief executive officer of Portola. "His
knowledge, network and track record are directly and immediately
relevant and applicable as we enter the pivotal phases of our three
near-term pipeline opportunities that could transform Portola to a
fully integrated commercial biopharmaceutical company in 2016."
Dr. Stump's career in the biotechnology industry spans more than
20 years. Prior to joining Human Genome Sciences, he held roles of
increasing responsibility at Genentech, Inc., most recently as vice
president, clinical research. Earlier in his career, he was named a
Genentech Fellow. Before joining Genentech, he was an associate
professor of medicine and biochemistry at the University of
Vermont. Dr. Stump earned an A.B. from Earlham College and an M.D.
at Indiana University, followed by residency and fellowship
training in internal medicine, hematology and oncology, and
biochemistry at the University of Iowa. He completed postgraduate
training in hemostasis and thrombosis at the University of Leuven,
Belgium. He is board certified in internal medicine, hematology and
medical oncology. He is a Fellow of the American College of
Physicians and the Council on Arteriosclerosis, Thrombosis and
Vascular Biology of the American Heart Association. He is also a
member of the board of directors of Sunesis Pharmaceuticals, Inc.
and MacroGenics, Inc.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing its three wholly-owned programs using novel biomarker and
genetic approaches that may increase the likelihood of clinical,
regulatory and commercial success of its potentially life-saving
therapies. These programs include betrixaban, an oral, once-daily
Factor Xa inhibitor being evaluated in the APEX Phase 3 study for
prophylaxis of venous thromboembolism; andexanet alfa, a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a Syk/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective Syk inhibitors for inflammatory conditions.
For more information, visit www.portola.com and follow the Company
on Twitter @Portola_Pharma.
Forward-looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to our intention to launch
the two late-stage products in our thrombosis franchise and advance
the clinical development of our product candidate in hematologic
cancer and other statements regarding the development of our
product candidates. Risks that contribute to the uncertain nature
of the forward-looking statements include: the accuracy of
Portola's estimates regarding its ability to initiate and/or
complete its clinical trials; the success of Portola's clinical
trials and the demonstrated efficacy of Portola's product
candidates to the satisfaction of regulatory authorities; the
accuracy of Portola's estimates regarding its expenses and capital
requirements; Portola's ability to manufacture andexanet alfa;
regulatory developments in the United States and foreign countries;
Portola's ability to obtain and maintain intellectual property
protection for its product candidates; and the loss of key
scientific or management personnel. These and other risks and
uncertainties are described more fully in Portola's most recent
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K, which was filed on March 2, 2015, and
Quarterly Report on Form 10-Q, which was filed on August 5, 2015.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Portola
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
CONTACT: Investor Contact:
Michele Mantynen
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024